Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10481909 | 0.93 | SIGMAR1 (0.48) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL7700283 | 0.89 | CYP1A2 (0.50) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL30424192 | 0.86 | SIGMAR1 (0.48) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL9216856 | 0.85 | CYP1A2 (0.48) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4322750 | 0.82 | MTNR1A (0.45) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL9800436 | 0.82 | CYP1A2 (0.58) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5830948 | 0.82 | GPR84 (0.59) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1610599 | 0.81 | CYP1A2 (0.46) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL143128 | 0.81 | MTNR1A (0.47) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6028071 | 0.81 | TLR8 (0.50) | SIGMAR1MTNR1ACYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| CN-1204262-C | Method for producing optically active amines | BASF AG (DE) | 2005-06-01 | — | — | CN | disclosed |
| CN-1195764-C | Transition metal complex, preparation method and use thereof | BASF AG (DE) | 2005-04-06 | — | — | CN | disclosed |
| CN-1496991-A | Chirality monophosphorous compound and its transition metal compound | — | 2004-05-19 | — | — | CN | disclosed |
| CN-1493576-A | Chiral diphosphorus compound and its transition metal compounding product | — | 2004-05-05 | — | — | CN | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| CN-1131233-C | Carbohydrate derivatives and their solid-phase synthesis | BASF AG (DE) | 2003-12-17 | — | — | CN | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| CN-1399687-A | Process for preparing optically active amines | BASF AG (DE) | 2003-02-26 | — | — | CN | disclosed |
| CN-1330074-A | Transition metal complex, preparation method and use thereof | BASF AG (DE) | 2002-01-09 | — | — | CN | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| CN-1072227-C | Optically active diphosphine ligands | BASF AG (DE) | 2001-10-03 | — | — | CN | disclosed |
| CN-1219937-A | Carbohydrate derivatives and their solid-phase synthesis | BASF AG (DE) | 1999-06-16 | — | — | CN | disclosed |
| CN-1202492-A | Optically active diphosphine ligands | BASF AG (DE) | 1998-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | SIGMAR1 950/4885MTNR1A 886/4885CYP1A2 297/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | SIGMAR1 950/4885MTNR1A 886/4885CYP1A2 297/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | SIGMAR1 3663/4885MTNR1A 898/4885CYP1A2 4073/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | SIGMAR1 3663/4885MTNR1A 898/4885CYP1A2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.